What's new in melanoma? Combination!

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Ascierto, Paolo A ^a   Marincola, Francesco M ^b   Atkins, Michael B ^c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINIMETINIB; COBIMETINIB; DABRAFENIB; DACARBAZINE; DURVALUMAB; ENCORAFENIB; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; TALIMOGENE LAHERPAREPVEC; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CUTANEOUS MELANOMA; DISEASE CONTROL RATE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; EVIDENCE BASED MEDICINE; FEVER; GENERAL PATHOLOGICAL PARAMETERS; HUMAN; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL RESPONSE RATE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; METABOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CLINICAL TRIALS AS TOPIC; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS;

EID: 84936764110     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0582-1     Document Type: Editorial

References (25)

1. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M et al (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867-1876
2. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J et al (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371:1877-1888
3. Larkin JMG, Yan Y, McArthur GA, Ascierto PA, Liszkay G, Maio M et al (2015) Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. J Clin Oncol 33 (suppl; abstr 9006)
4. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud FG, Larkin JMG, et al (2015) Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. J Clin Oncol 33 (suppl; abstr 102)
5. Flaherty K, Daud A, Weber JS, Sosman JA, Kim K, Gonzalez R et al (2014) Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D + T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM). J Clin Oncol 32:5s (suppl; abstr 9010^)
6. Sullivan RJ, Weber JS, Patel SP, Dummer R, Miller WH, Cosgrove D et al (2015) A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. J Clin Oncol 33 (suppl; abstr 9007)
7. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med [Epub ahead of print]
8. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006-2017
9. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526
10. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H et al (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16:522-530
11. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454
12. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133
13. Chapman PB, D'Angelo SP, Wolchok JD (2015) Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. N Engl J Med 372:2073-2074
14. Puzanov I, Milhem MM, Andtbacka RHI, Minor DR, Hamid O, Li A et al (2015) Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol 33 (suppl; abstr 9063)
15. Puzanov I, Callahan MK, Linette GP, Patel SP, Luke JL, Sosman JA et al (2014) Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). J Clin Oncol 32:5s (suppl; abstr 2511)
16. Ribas A, Butler M, Lutzky J, Lawrence DP, Robert C, Miller W et al (2015) Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. J Clin Oncol 33 (suppl; abstr 3003)
17. Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu W-J et al (2015) Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J Clin Oncol 33 (suppl; abstr 3001)
18. Choueiri TK, Fishman MN, Escudier B, McDermott DF, Kluger HM, Stadler WM et al (2015) Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): association of biomarkers with clinical outcomes. J Clin Oncol 33 (suppl; abstr 4500)
19. Le DT, Uram JE, Wang H, Bartlett B, Kemberling H, Eyring A et al (2015) PD-1 blockade in tumors with mismatch repair deficiency. J Clin Oncol 33 (suppl; abstr LBA100)
20. Ascierto PA, Streicher HZ, Sznol M (2010) Melanoma: a model for testing new agents in combination therapies. J Transl Med 8:38
21. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375-384
22. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320-330
23. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521-2532
24. Puzanov I, Dummer R, Schachter J, Pavlick AC, Gonzalez R, Ascierto PA et al (2015) Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL). J Clin Oncol 33 (suppl; abstr 3012)
25. Joseph R, Elassaiss-Schaap J, Wolchok JD, Joshua AM, Ribas A, Hodi FS et al (2014) Baseline tumor size (BTS) and PD-L1 expression are independently associated with clinical outcomes in patients (pts) with metastatic melanoma (MM) treated with pembrolizumab (pembro; MK-3475). Pigment Cell Melanoma Res 27;1169:1188 (abstract)